sc 58125 has been researched along with celecoxib in 8 studies
| Studies (sc 58125) | Trials (sc 58125) | Recent Studies (post-2010) (sc 58125) | Studies (celecoxib) | Trials (celecoxib) | Recent Studies (post-2010) (celecoxib) |
|---|---|---|---|---|---|
| 93 | 0 | 15 | 5,273 | 843 | 2,428 |
| Protein | Taxonomy | sc 58125 (IC50) | celecoxib (IC50) |
|---|---|---|---|
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | 0.021 | |
| Prostaglandin E synthase | Homo sapiens (human) | 0.4825 | |
| Histone deacetylase 3 | Homo sapiens (human) | 1.637 | |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 7.9667 | |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.057 | |
| Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | 6.5 | |
| Cytochrome c oxidase subunit 2 | Ovis aries (sheep) | 0.0881 | |
| Catechol O-methyltransferase | Mus musculus (house mouse) | 0.036 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 0.371 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 0.1555 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.0925 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 5.271 | |
| Procathepsin L | Homo sapiens (human) | 0.56 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 7.308 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.07 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.295 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.002 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.516 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.12 | |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 3.6401 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3.5499 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 7.308 | |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | 0.006 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 6.276 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3818 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.4028 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 7.6 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1.637 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.03 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.6343 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 7.7 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.431 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.045 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1.411 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.81 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 0.016 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.05 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.3 | |
| Prostaglandin G/H synthase 1 | Canis lupus familiaris (dog) | 5.57 | |
| Cyclooxygenase-2 | Canis lupus familiaris (dog) | 0.9 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1.637 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1.637 | |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | 0.04 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1.14 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1.637 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertenshaw, SR; Burton, EG; Carter, JS; Cogburn, JN; Collins, PW; Docter, S; Graneto, MJ; Gregory, SA; Isakson, PC; Koboldt, CM; Lee, LF; Malecha, JW; Miyashiro, JM; Penning, TD; Perkins, WE; Rogers, RS; Rogier, DJ; Seibert, K; Talley, JJ; Veenhuizen, AW; Yu, SS; Zhang, YY | 1 |
| Baurin, N; Chavatte, P; Lesieur, D; Marot, C; Yous, S | 1 |
| Hagmann, WK | 1 |
| Chen, CS; Chiu, HC; Gunn, JS; Kulp, SK; Schlesinger, LS; Soni, S; Yang, J | 1 |
| Meanwell, NA | 1 |
| Bhardwaj, A; Dzandzi, J; Tietz, O; Valliant, JF; Wuest, F | 1 |
| Chang, Q; Ding, J; Gong, S | 1 |
| Hu, Q; Qiu, XW; Wang, ZR; Xu, ZQ; Zhang, J | 1 |
8 other study(ies) available for sc 58125 and celecoxib
| Article | Year |
|---|---|
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Hyperalgesia; Isoenzymes; Magnetic Resonance Spectroscopy; Male; Membrane Proteins; Molecular Structure; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides | 1997 |
Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis.
Topics: Benzene Derivatives; Binding Sites; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cyclopentanes; Imidazoles; Isoenzymes; Isoxazoles; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrroles; Quantitative Structure-Activity Relationship; Spiro Compounds; Thiophenes | 2001 |
The many roles for fluorine in medicinal chemistry.
Topics: Animals; Chemistry, Pharmaceutical; Enzyme Inhibitors; Fluorine; Fluorine Compounds; Humans; Protein Binding; Stereoisomerism | 2008 |
Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis.
Topics: Animals; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 2 Inhibitors; Francisella tularensis; Humans; Lactones; Mice; Microbial Sensitivity Tests; Pyrazoles; Sulfonamides; Sulfones | 2009 |
Synopsis of some recent tactical application of bioisosteres in drug design.
Topics: Cytochrome P-450 Enzyme System; Drug Design | 2011 |
Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Iodine Radioisotopes; Molecular Docking Simulation; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Sulfones | 2016 |
Inhibitory effects of Celecoxib and Sc-58125 on proliferation of human carcinoma of larynx Hep-2 in vitro.
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Humans; Laryngeal Neoplasms; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2005 |
[Effects of selective cyclooxygenase-2 inhibitor on proliferation and apoptosis of human bladder cancer cell line T24].
Topics: Apoptosis; bcl-2-Associated X Protein; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Flow Cytometry; Humans; Indomethacin; Inhibitory Concentration 50; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Urinary Bladder Neoplasms | 2007 |